Daywatch: Purple Heart returned to family of WWII veteran
Good morning, Chicago.
In the hard-fought campaign to liberate the Philippines during World War II, 22-year-old Army Cpl. Henry Van Der Noord of suburban Lansing was hit with shrapnel during a key battle on the island of Luzon.
Van Der Noord survived — as did three brothers who also served their country in the war — and earned a Purple Heart for the combat injury he suffered in May 1945.
This month, as Memorial Day approached, Van Der Noord's firstborn grandchild Chris Reed held the heart-shaped medal for the first time in about 25 years after Illinois Treasurer Michael Frerichs presented it to him during a poignant ceremony in Atlanta.
Read the full story from the Tribune's Christy Gutowski.
Here are the top stories you need to know to start your day, including how Chicago aldermen voted on a plan designed to curb 'teen takeovers,' remembering actor George Wendt and 15 restaurant and bar specials over Memorial Day weekend.
Today's eNewspaper edition | Subscribe to more newsletters | Asking Eric | Horoscopes | Puzzles & Games | Today in History
A federal judge ruled that U.S. officials must retain custody and control of migrants apparently removed to South Sudan in case he orders their removals were unlawful.
U.S. District Judge Brian E. Murphy in Massachusetts issued the ruling after an emergency hearing, after attorneys for immigrants said the Trump administration appears to have begun deporting people from Myanmar and Vietnam to South Sudan — despite a court order restricting removals to other countries.
A group representing victims sexually abused by Catholic priests alleged Pope Leo XIV has exhibited a 'pattern of failure to properly investigate abuse claims,' including allegations that the Chicago-born pontiff mishandled multiple cases while in prominent leadership roles in the city.
The senators sent a letter to Prime Healthcare founder, chairman and CEO Dr. Prem Reddy expressing concern about the changes and asking him to answer questions about the health system's plans.
'Prime Healthcare has only operated these eight Illinois hospitals for two months, and there are already profound concerns about patients losing access to care,' the Senate Democrats wrote in their letter.
Chicago aldermen advanced a measure yesterday designed to curb so-called teen takeovers with curfews after the ordinance's lead sponsor made a pivotal tweak to the measure.
Downtown Ald. Brian Hopkins substituted a new version of his teen curfew ordinance that places the power to declare three-hour 'snap curfews' targeting specific areas solely in the hands of Chicago's police superintendent.
Illinois gun dealers were unable to sell ammunition yesterday after a portion of the Illinois State Police website used for verifying firearm owner ID cards was shut down for maintenance.
The state police said the website will remain inactive until 4 p.m. today.
Naperville police have yet again made a firearm-related arrest in the Naperville Topgolf parking lot. There have now been 10 such arrests in or near the business' lot this year.
Luis Robert Jr. briefly took up the role of a general manager when the topic of trade talks came up yesterday afternoon at Rate Field.
'I think right now, as my season is going, I don't think anybody is going to take a chance on me,' Robert said through an interpreter in a lighthearted moment.
Robert's name had been mentioned in trade speculation during the offseason. The chatter hasn't died down much in the regular season, even though the Chicago White Sox center fielder is off to a slow start.
NFL owners have unanimously approved permission for players to participate in flag football in the 2028 Olympics.
The flag football vote was a given. The hard part for league owners this week at the Omni Viking Lakes Hotel is determining the fate of the tush push.
Memorial Day marks the unofficial start of summer, offering a long weekend to enjoy the weather while drinking plenty of rosé and beer and feasting on food best enjoyed outdoors like hot dogs and seafood boils. The weekend kicks off festival season, but also offers the opportunity to mark the holiday by supporting veterans and service members. However you'd like to celebrate, these 15 events have you covered.
George Wendt, the actor and comedian who cut his teeth at Chicago's improvisational comedy troupe Second City before finding fame as part of the ensemble cast of the beloved 1980s NBC sitcom 'Cheers,' has died. He was 76.
Those who knew Wendt personally could attest to his unassuming, approachable manner, and the fact that an actor with such tremendous Hollywood success never allowed stardom to go to his head. Instead, Wendt endeared himself to fans both onstage in TV, films and stage productions and also offstage — particularly in his native Chicago — as a down-to-Earth, sports-loving guy always quick with wry, Norm-ish observations and a perpetual insistence that his writers were the ones doing the real work.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Chrononutrition guide: Is when you eat as important as what you eat?
Americans have long heard about the health benefits of adhering to diets rich in fresh produce and whole grains and low in red meat and processed sugars. But they may not be aware of how meal timing can affect their health. A recent publication from the UF/IFAS department of food science and human nutrition describes chrononutrition, an emerging field of study that connects eating with circadian rhythm, the body's 24-hour internal clock. How someone schedules meals throughout the day can impact their weight and body mass index (BMI) as well as increase their odds of developing cardiometabolic diseases, including type 2 diabetes, according to the authors of the publication, an Ask IFAS guide. 'Healthy eating is not only what you eat but also how much you eat and when,' said doctoral candidate Kaylyn Koons, the publication's lead author. Franz Halberg, a Romanian-born physician, introduced the idea of chrononutrition in 1967. The concept is based on the premise that the sleep and wake cycle regulates bodily functions, including metabolism and digestion, so the timing, frequency and consistency of food intake affects health. There is a broad range of eating behaviors that influence chrononutrition, according to the UF/IFAS guide. One of the key behaviors relates to the 'eating window,' the time frame between the first meal of the day and the last. Optimizing that window — typically between 8 and 12 hours — could realign food intake with the circadian clock. In fact, a systematic review of studies on time-restricted eating with an eating window of 12 hours or less found an average weight loss of 3%, along with reductions in fasting blood glucose, systolic blood pressure, waist circumference, and LDL cholesterol levels. Many eating behaviors related to poor chrononutrition center around evening food consumption. Eating at or after 8 p.m. is associated with weight gain and metabolic disorders, for example. Potential reasons include the prevalence of poorer food choices at night and late eaters' propensity to stay up late, which can negatively impact sleep. Evening latency, the amount of time that lapses between eating the last meal of the day and sleeping, can also play a part, according to the guide. It describes a 2023 study of Malaysian college students which found that those who didn't observe a delay between eating dinner and sleeping were more likely to be underweight. 'This finding may seem counterintuitive because you might expect this behavior would reduce energy expenditure and promote weight gain rather than weight loss,' Koons said. 'But it could be associated with other adverse chrononutrition habits such as skipping meals or irregular meal timing, which lead to an overall reduced calorie intake.' Koons recommends anyone desiring to improve their chrononutrition examine their eating behaviors and identify chrononutrition-related behaviors that may be negatively affecting their health. Then they can set attainable goals to reduce the frequency of those behaviors. Patience is key, however, she said. 'Eating habits tend to be ingrained in routine and become habitual,' Koons said. 'It's important to remember that behavior change is difficult, and it takes time.' This article originally appeared on Tallahassee Democrat: When you eat may be as important as what you eat
WebMD
7 hours ago
- WebMD
Navigating Skincare: Keloids, Climate, and Consistency
As a child, the dermatologist was the doctor I visited most frequently. Between dark spots on my face, severely chapped lips, and dry skin during the winter, I was always being prescribed a new ointment or remedy to try. Today, the first two issues have been resolved thanks to healthier eating habits and finding the right skin care and lip products for me. However, I still deal with dry skin not only in the winter but throughout most of the year. I've noticed that my keloid scars, along with the surrounding areas, are particularly prone to dry skin. For those unfamiliar with keloids, they're a growth of extra scar tissue that happens where the skin has healed after an injury or surgical procedure. I've been dealing with them since I was in middle school, having developed a large one on the back of my earlobe following my ear piercing. My breast cancer treatment and surgeries introduced several more keloids into my life, including at the site of my chemo port, in the radiated area of my breast, and the largest one – a long scar across my back from one of my breast reconstruction surgeries. While they're not painful, they're often dry, itchy, and hard to reach in certain spots (like the scar on my back, which can be tricky to moisturize properly because of its location). I recently moved from Atlanta to Chicago, which has caused me to rethink my winter skin care routine, especially when it comes to my keloid-prone skin. The cold, dry air makes my scars even itchier and more dehydrated, so I've had to adjust my approach. I've found that layering an oil-based body lotion with a body oil helps my skin lock in moisture longer. Additionally, applying Vaseline to my keloids every morning and night has provided extra relief. My need for a tailored skin care routine isn't just about adapting to the colder months. It's a reminder of how I've had to advocate for my skin's unique needs throughout my health journey – from childhood to my breast cancer treatment. Many aspects of health care don't always consider the needs of people with melanin-rich skin, something I've learned time and time again. One example of this happened before starting radiation, when I was informed that the radiated area would turn darker, like a tan. However, what I experienced was nothing like a cute summer tan – my skin turned completely black and became very tender and painful. I realized early on that the standard skin care recommendations wouldn't work for my skin's needs, requiring me to look for alternatives. Taking proper care of my skin is a constant journey, especially when navigating different climates and changing seasons. I usually shop based on reviews, which has quickly taught me that what works for one person might not work for another, and that's OK. The key is to listen to your body, stay consistent, and adjust your routine to support your skin's unique needs. Whether it's layering oils during the winter or finding products that soothe and hydrate, prioritizing what works best for you is key – your skin will thank you for it.
Medscape
9 hours ago
- Medscape
Can New Combo Fill ‘Unmet Need' in R/R Hodgkin Lymphoma?
Acimtamig, a first-in-class CD30/CD16A bispecific innate cell engager (ICE), combined with an off-the-shelf cord-blood derived natural killer cell product (AlloNK), shows safety and efficacy in the treatment of patients with relapsed or refractory (R/R) classical Hodgkin lymphoma, who otherwise have poor prognoses. 'Acimtamig in combination with AlloNK shows promising efficacy with a well-managed safety profile with the potential to address an unmet need in patients with R/R Hodgkin lymphoma who have exhausted standard-of-care treatment options,' said first author Joseph Maakaron, MD, of the Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, in presenting the findings at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago. Patients with classical Hodgkin lymphoma who relapse after standard-of-care treatments, including chemotherapy, brentuximab vedotin, and checkpoint inhibitors, have few remaining treatment options. Acimtamig has previously shown some efficacy as monotherapy in the treatment of Hodgkin lymphoma, and when further combined with an allogenic cord blood derived natural killer cell product, encouraging objective response rates were observed in a proof-of-concept study. To test the approach in a more rigorous multicenter trial, Maakaron and colleagues conducted the current open-label phase 2 LuminICE-203 trial, enrolling 24 patients with R/R Hodgkin lymphoma. For the study, the patients were treated in one of four cohorts investigating two doses of acimtamig (200 mg or 300 mg weekly flat dosing for 6 weeks) in combination with two dose levels of AlloNK after standard lymphodepletion of up to three cycles and followed by a randomized part using the Simon two-stage design. While the patients had a median age of 42.5 years, the range was wide, ranging from age 23 to 80 years, and 16 (67%) were men. About two thirds of patients (66.7%) had extranodal disease, and they had all been heavily pre-treated with brentuximab vedotin and programmed cell death protein 1 inhibitors, with a median of 4.5 prior lines of treatment, including previous stem cell transplant and CAR T cell therapy among 14 (58%) patients. 'The patients had essentially exhausted all standard-of-care therapy options,' Maakaron emphasized. As of the latest cut-off, the study achieved its primary end point of an objective response rate, with a rate of 88% among the patients, with 14 (58%) achieving complete responses. Across all four dose cohorts, clinically meaningful deep responses were seen, with 10 ongoing responses. A progression-free survival estimate of 61% was observed at 6 months. More robust maximum peaks were observed after the third infusion, which was presumed to be due to a steady state that had been achieved at that time, he added. The safety profile was consistent with previous reports, with the therapy combination being well tolerated. The most common treatment-related side effects were mild to moderate infusion-related reactions, occurring in 50% of patients. There were no cases of graft vs host disease or immune effector cell-associated neurotoxicity syndrome, and cytokine release syndrome (CRS) was reported in six patients shortly after infusion. All treatment-emergent adverse events including infusion-related reactions and CRS events were controlled with standard-of-care interventions and quickly resolved. There were no fatal treatment-emergent adverse events. 'Acimtamig with AlloNK may provide a safe, effective, and durable new therapeutic option for patients with R/R Hodgkin lymphoma, with a progression-free survival estimate of 61% at 6 months,' Maakaron said. 'These early results support the co-administration approach of acimtamig with an off-the-shelf, commercially scalable, allogenic, cryopreserved natural killer cell product in a multicenter setting,' he said. Study Shows Best Response Rates to Date Commenting on the findings at the meeting, Sarah C. Rutherford, MD, associate professor of clinical medicine at Weill Cornell Medicine in New York City, said the need for better treatment options for those who have relapsed after standard therapies is pressing. 'This is really an unmet need in the field,' she underscored. 'Novel treatments in R/R classic Hodgkin lymphoma after brentuximab vedotin, checkpoint inhibitors, and autologous transplant are limited, and most don't really work that well.' 'We tend to use single-agent chemotherapies, repeat checkpoint inhibitors, and radiation, but these patients really suffer because of that, and clinical trial options have been lacking.' Rutherford noted that, with the innovative combination, safety and tolerability were important concerns. 'I was really struck by the tolerability of this regimen, with only five patients having grade 3 and one [having] grade 4 treatment-emergent adverse events.' Furthermore, the response rates were impressive, she noted. 'These are the best response rates observed to date in the post-brentuximab vedotin and checkpoint inhibitor setting, and the toxicities appear manageable,' she said. 'I think it's going to be unlikely to be as widely adopted as checkpoint inhibitors because of the nature of the cellular therapy approach, but I do think this is a very promising agent,' Rutherford said. 'I think it's the current best available trial option, and in the future, some version of this could become a third-line therapy in this disease.'
